百克生物(688276.SH)：吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获得批准

Core Viewpoint - The company, Baike Biotechnology (688276.SH), has received approval from the National Medical Products Administration for the clinical trial of its combined vaccine, which targets whooping cough, diphtheria, tetanus, and Haemophilus influenzae type b [1] Group 1 - The approved vaccine is referred to as the "acellular combined whooping cough-diphtheria-tetanus and Hib vaccine" [1] - This vaccine is designed for infants aged 2 months and older, aiming to stimulate immune responses to prevent invasive infections caused by the targeted diseases [1] - The vaccine provides simultaneous protection against whooping cough, diphtheria, tetanus, and invasive infections from Haemophilus influenzae type b [1]